5-4 Nihonbashi-Honcho 1-chome
8 articles with Nichi-Iko Pharmaceutical
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
Nichi-Iko Pharmaceutical Co., Ltd. ("Nichi-Iko") and Sagent Pharmaceuticals, Inc., a Nichi-Iko Group Company ("Sagent"), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that their Canadian subsidiary, Omega Laboratories Limited ("Omega"), has been found acceptable for manufacturing FDA-approved products in its initial Establishment Inspection Report issued by the U.S. FDA.
Nichi-Iko Pharmaceutical Co., Ltd. and Sagent Pharmaceuticals, Inc. announced that Sagent has acquired an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals.
Nichi-Iko Announces Results Of Tender Offer To Purchase All Of The Outstanding Shares Of Common Stock Of Sagent Pharma
Shepard Vision, A Wholly-Owned Subsidiary Of Nichi-Iko Commences All-Cash Tender Offer Of $21.75 Net Per Share To Acquire All Outstanding Shares Of Sagent Pharma
Towa Pharmaceutical Co., Ltd., Sawai Pharmaceutical Co., Ltd., Nichi-iko Pharmaceutical Form Basic Agreement To Set Generic Product Standards